Epidemiological studies document a positive and independent association between metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS). In the male, the pathogenesis of MetS-related LUTS involves a complex interplay among pathophysiological mechanisms mainly affecting the prostate and the bladder. Recently, hypogonadism has been recognized as a key factor bridging MetS and LUTS. Preclinical data have evidenced that MetS-induced hypogonadism is associated with alterations not only of the prostate but also of the bladder, and testosterone supplementation can counteract both. Interestingly, testosterone also shows a marked effect on the bladder, preventing the MetS-related RhoA/ROCK hyperactivation, which drives the pathogenesis of bladder overactivity and LUTS. The precise mechanisms through which testosterone exerts its protective action on the LUT remains to be fully elucidated; however, indirect (through improved cardiometabolic status) and direct (through local androgen receptor-mediated pathways) actions are both likely to play a role.
Testosterone protects the lower urinary tract from metabolic syndrome-induced alterations / Linda Vignozzi, Annamaria Morelli, Giovanni Corona, Arcangelo Sebastianelli, Sergio Serni, Mauro Gacci, Luciano Adorini, Mario Maggi. - In: HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION. - ISSN 1868-1883. - STAMPA. - 11:(2012), pp. 329-337. [10.1515/hmbci-2012-0029]
Testosterone protects the lower urinary tract from metabolic syndrome-induced alterations
Linda Vignozzi;Annamaria Morelli;Giovanni Corona;Arcangelo Sebastianelli;Sergio Serni;Mauro Gacci;Mario Maggi
2012
Abstract
Epidemiological studies document a positive and independent association between metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS). In the male, the pathogenesis of MetS-related LUTS involves a complex interplay among pathophysiological mechanisms mainly affecting the prostate and the bladder. Recently, hypogonadism has been recognized as a key factor bridging MetS and LUTS. Preclinical data have evidenced that MetS-induced hypogonadism is associated with alterations not only of the prostate but also of the bladder, and testosterone supplementation can counteract both. Interestingly, testosterone also shows a marked effect on the bladder, preventing the MetS-related RhoA/ROCK hyperactivation, which drives the pathogenesis of bladder overactivity and LUTS. The precise mechanisms through which testosterone exerts its protective action on the LUT remains to be fully elucidated; however, indirect (through improved cardiometabolic status) and direct (through local androgen receptor-mediated pathways) actions are both likely to play a role.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.